Recent advances and updated guidelines in the management of chemotherapy-induced nausea and vomiting.

Lee Schwartzberg, Steven M. Grunberg, Mark G. Kris

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

One of the most dreaded side effects of anticancer treatment, chemotherapy-induced nausea and vomiting (CINV) plays a significant role in cancer patients' morbidity and quality of life. The management of CINV has been refined over the past several decades, and CINV can now be addressed with targeted prophylactic medications aimed at inhibiting the molecular pathways involved in emesis, including serotonin receptor antagonists and neurokinin-1 receptor antagonists. Advances in the understanding of the physiology of CINV, coupled with the introduction of several agents that inhibit activation of these receptors, are reflected in current CINV guidelines. These guidelines, which are largely similar, provide recommendations based on expert review of available clinical trial data. Despite the availability of effective prophylaxis, many patients still suffer from CINV. To minimize these side effects, clinicians should ensure widespread adoption and implementation of at least 1 CINV guideline in their practice. Even when the recommendations are followed, a small group of patients continue to experience CINV, often in the form of nausea, for which few treatments are effective. Current and future studies will begin to delineate the specific pathways for the development of nausea, hopefully leading to the identification of novel agents and regimens with improved efficacy in this setting.

Original languageEnglish (US)
JournalClinical Advances in Hematology and Oncology
Volume9
Issue number11 Suppl 27
StatePublished - Nov 2011

Fingerprint

Nausea
Vomiting
Guidelines
Drug Therapy
Neurokinin-1 Receptor Antagonists
Serotonin Antagonists
Quality of Life
Clinical Trials
Morbidity
Therapeutics

All Science Journal Classification (ASJC) codes

  • Oncology
  • Hematology

Cite this

Recent advances and updated guidelines in the management of chemotherapy-induced nausea and vomiting. / Schwartzberg, Lee; Grunberg, Steven M.; Kris, Mark G.

In: Clinical Advances in Hematology and Oncology, Vol. 9, No. 11 Suppl 27, 11.2011.

Research output: Contribution to journalArticle

@article{11987e7fa8cf49b4b835992b8661ee2d,
title = "Recent advances and updated guidelines in the management of chemotherapy-induced nausea and vomiting.",
abstract = "One of the most dreaded side effects of anticancer treatment, chemotherapy-induced nausea and vomiting (CINV) plays a significant role in cancer patients' morbidity and quality of life. The management of CINV has been refined over the past several decades, and CINV can now be addressed with targeted prophylactic medications aimed at inhibiting the molecular pathways involved in emesis, including serotonin receptor antagonists and neurokinin-1 receptor antagonists. Advances in the understanding of the physiology of CINV, coupled with the introduction of several agents that inhibit activation of these receptors, are reflected in current CINV guidelines. These guidelines, which are largely similar, provide recommendations based on expert review of available clinical trial data. Despite the availability of effective prophylaxis, many patients still suffer from CINV. To minimize these side effects, clinicians should ensure widespread adoption and implementation of at least 1 CINV guideline in their practice. Even when the recommendations are followed, a small group of patients continue to experience CINV, often in the form of nausea, for which few treatments are effective. Current and future studies will begin to delineate the specific pathways for the development of nausea, hopefully leading to the identification of novel agents and regimens with improved efficacy in this setting.",
author = "Lee Schwartzberg and Grunberg, {Steven M.} and Kris, {Mark G.}",
year = "2011",
month = "11",
language = "English (US)",
volume = "9",
journal = "Clinical Advances in Hematology and Oncology",
issn = "1543-0790",
publisher = "Millennium Medical Publishing, Inc.",
number = "11 Suppl 27",

}

TY - JOUR

T1 - Recent advances and updated guidelines in the management of chemotherapy-induced nausea and vomiting.

AU - Schwartzberg, Lee

AU - Grunberg, Steven M.

AU - Kris, Mark G.

PY - 2011/11

Y1 - 2011/11

N2 - One of the most dreaded side effects of anticancer treatment, chemotherapy-induced nausea and vomiting (CINV) plays a significant role in cancer patients' morbidity and quality of life. The management of CINV has been refined over the past several decades, and CINV can now be addressed with targeted prophylactic medications aimed at inhibiting the molecular pathways involved in emesis, including serotonin receptor antagonists and neurokinin-1 receptor antagonists. Advances in the understanding of the physiology of CINV, coupled with the introduction of several agents that inhibit activation of these receptors, are reflected in current CINV guidelines. These guidelines, which are largely similar, provide recommendations based on expert review of available clinical trial data. Despite the availability of effective prophylaxis, many patients still suffer from CINV. To minimize these side effects, clinicians should ensure widespread adoption and implementation of at least 1 CINV guideline in their practice. Even when the recommendations are followed, a small group of patients continue to experience CINV, often in the form of nausea, for which few treatments are effective. Current and future studies will begin to delineate the specific pathways for the development of nausea, hopefully leading to the identification of novel agents and regimens with improved efficacy in this setting.

AB - One of the most dreaded side effects of anticancer treatment, chemotherapy-induced nausea and vomiting (CINV) plays a significant role in cancer patients' morbidity and quality of life. The management of CINV has been refined over the past several decades, and CINV can now be addressed with targeted prophylactic medications aimed at inhibiting the molecular pathways involved in emesis, including serotonin receptor antagonists and neurokinin-1 receptor antagonists. Advances in the understanding of the physiology of CINV, coupled with the introduction of several agents that inhibit activation of these receptors, are reflected in current CINV guidelines. These guidelines, which are largely similar, provide recommendations based on expert review of available clinical trial data. Despite the availability of effective prophylaxis, many patients still suffer from CINV. To minimize these side effects, clinicians should ensure widespread adoption and implementation of at least 1 CINV guideline in their practice. Even when the recommendations are followed, a small group of patients continue to experience CINV, often in the form of nausea, for which few treatments are effective. Current and future studies will begin to delineate the specific pathways for the development of nausea, hopefully leading to the identification of novel agents and regimens with improved efficacy in this setting.

UR - http://www.scopus.com/inward/record.url?scp=84860210117&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84860210117&partnerID=8YFLogxK

M3 - Article

VL - 9

JO - Clinical Advances in Hematology and Oncology

JF - Clinical Advances in Hematology and Oncology

SN - 1543-0790

IS - 11 Suppl 27

ER -